ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

petrelintide

Also written as “Petrelintide” and “ZP8396”.

Its studies are mostly in Obesity · Overweight · Renal Insufficiency, led by 2 companies.

Drug pagePetrelintide: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 25, 202411 company-led studies, 5 open or runningCo-development: Zealand Pharma and Roche, Mar 2025Next primary completion: Apr 12, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Zealand Pharmaits history only71 open or runningphase 2since Oct 25, 2024Oct 14, 2021Apr 12, 2027phase 1 · NCT07682818
Hoffmann-La Roche44 open or runningphase 3since Sep 11, 2026May 11, 2026Nov 12, 2027phase 2 · NCT07589686
  • Named in Hoffmann-La Roche’s own pipeline as RG6849 petrelintide (Zealand), phase 3, as of Oct 22, 2026 (source).

Also a collaborator on its studies: Parexel, ICON Clinical Research and ICON.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Aug 6, 2023Named petrelintideINNProposed as its International Nonproprietary Name in WHO's List 129 · before, ZP8396
  2. Mar 12, 2025Roche develops it with Zealand PharmaCo-developmentTogether in the US and Europe; Roche alone elsewhere · announced · Roche
  3. May 11, 2026First study: phase 2 study in ObesityFirst studyNCT07589686 · 486 planned
  4. Sep 11, 20263 phase 3 studies in ObesityPhase 3 reachedNCT07843498, NCT07843485, NCT07843472

Ahead

  1. Nov 12, 2027Primary completion: phase 2 study in ObesityNCT07589686
  2. Oct 20, 2028Primary completion: phase 3 study in ObesityNCT07843485
  3. Dec 21, 2028Primary completion: phase 3 study in ObesityNCT07843498
  4. Jul 28, 2030Primary completion: phase 3 study in ObesityNCT07843472

TargetBeta

CALCR →read by rule
“Petrelintide is a long-acting amylin analog in development for weight management.”study text, by rule · the study

Other programs on CALCR

ProgramCompanyFurthest phaseStudies
cagrilintideNovo Nordiskphase 350
zenagamtideNovo Nordiskphase 336
eloralintideEli Lillyphase 326
ABBV-295AbbViephase 25
PF-08653945Pfizerphase 22
GUB014295AbbViephase 11
CagriSema ANovo Nordiskphase 11

Studies

All 4 Hoffmann-La Roche leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07843472Obesity · United States, Taiwan, United Kingdom3RecruitingJul 28, 20302,500
NCT07843498Obesity · United States3RecruitingDec 21, 20283,900
NCT07843485Obesity · United States3RecruitingOct 20, 2028600
NCT07589686Obesity2Not yet recruitingNov 12, 2027486

How it is read

Names in the registry

  • “Petrelintide”, 9 entries
  • “ZP8396”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.